Matinas Biopharma (NYSEAMERICAN:MTNB) Posts Quarterly Earnings Results

Matinas Biopharma (NYSEAMERICAN:MTNB) released its quarterly earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports.

Matinas Biopharma Price Performance

Matinas Biopharma stock opened at $0.64 on Friday. Matinas Biopharma has a 12-month low of $0.48 and a 12-month high of $3.09. The company has a market capitalization of $4.09 million, a price-to-earnings ratio of -0.32 and a beta of 1.61. The firm’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.75.

Institutional Investors Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.